Nkarta signs its name to an ambitious future with manufacturing hub for not one but multiple marketed drugs
Riding science out of Dario Campana’s famed lab in Singapore, West Coast biotech Nkarta has been a high-profile entry into the race for the industry’s first natural killer cell-based therapy. The biotech, miles away from a potential approval, is doubling down on its own ambition and setting up a manufacturing facility of the future far in advance.
Nkarta has signed a lease on an 88,000-square-foot facility in South San Francisco that will act as the biotech’s new headquarters as well as the home of its commercial manufacturing operations, the company said Wednesday.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.